Bristol Myers Squibb, Acceleron get FDA nod for Reblozyl to treat anaemia with lower-risk MDS

This article was originally published here

Myelodysplastic syndromes are a group of closely related blood cancers characterised by ineffective production of healthy red blood cells, white blood cells and platelets, which may cause anaemia

The post Bristol Myers Squibb, Acceleron get FDA nod for Reblozyl to treat anaemia with lower-risk MDS appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply